AU2002356469A1 - Methods of compositions for normalizing lipid levels in mammalian tissues - Google Patents

Methods of compositions for normalizing lipid levels in mammalian tissues Download PDF

Info

Publication number
AU2002356469A1
AU2002356469A1 AU2002356469A AU2002356469A AU2002356469A1 AU 2002356469 A1 AU2002356469 A1 AU 2002356469A1 AU 2002356469 A AU2002356469 A AU 2002356469A AU 2002356469 A AU2002356469 A AU 2002356469A AU 2002356469 A1 AU2002356469 A1 AU 2002356469A1
Authority
AU
Australia
Prior art keywords
cgrp
receptor
agonist
amylin
high affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2002356469A
Other languages
English (en)
Other versions
AU2002356469A2 (en
Inventor
Garth James Smith Cooper
Kerry Martin Loomes
Rachel Nancy Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
Protemix Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd
Publication of AU2002356469A2 publication Critical patent/AU2002356469A2/en
Publication of AU2002356469A1 publication Critical patent/AU2002356469A1/en
Priority to AU2009201147A priority Critical patent/AU2009201147A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
AU2002356469A 2001-11-26 2002-11-26 Methods of compositions for normalizing lipid levels in mammalian tissues Withdrawn AU2002356469A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009201147A AU2009201147A1 (en) 2001-11-26 2009-03-26 Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33342201P 2001-11-26 2001-11-26
NZ515731 2001-11-26
US60/333,422 2001-11-26
NZ51573101 2001-11-26
PCT/NZ2002/000262 WO2003045424A1 (en) 2001-11-26 2002-11-26 Methods of compositions for normalizing lipid levels in mammalian tissues

Publications (2)

Publication Number Publication Date
AU2002356469A2 AU2002356469A2 (en) 2003-06-10
AU2002356469A1 true AU2002356469A1 (en) 2003-06-10

Family

ID=26652295

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002356469A Withdrawn AU2002356469A1 (en) 2001-11-26 2002-11-26 Methods of compositions for normalizing lipid levels in mammalian tissues
AU2009201147A Abandoned AU2009201147A1 (en) 2001-11-26 2009-03-26 Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009201147A Abandoned AU2009201147A1 (en) 2001-11-26 2009-03-26 Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues

Country Status (6)

Country Link
EP (1) EP1461068A4 (de)
JP (1) JP2005523418A (de)
CN (1) CN1617737A (de)
AU (2) AU2002356469A1 (de)
CA (1) CA2471833A1 (de)
WO (1) WO2003045424A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324234A (zh) 1998-09-25 2001-11-28 格利科克斯有限公司 果糖胺氧化酶,拮抗剂和抑制剂
ES2386782T3 (es) 2002-03-08 2012-08-30 Philera New Zealand Limited Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
PT1778618E (pt) 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US9708393B2 (en) 2011-05-20 2017-07-18 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP4115905A1 (de) 2011-05-20 2023-01-11 H. Lundbeck A/S Anti-cgrp-zusammensetzungen und verwendung davon
EP2709662B1 (de) 2011-05-20 2019-07-31 AlderBio Holdings LLC Verwendung von anti-cgrp- oder anti-cgrp-r-antikörpern oder antikörperfragmenten zur behandlung oder prävention chronischer und akuter formen von diarrhöe
EP3016684B1 (de) * 2013-07-03 2022-02-23 H. Lundbeck A/S Regulierung des glucosestoffwechsels mit anti-cgrp-antikörpern
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
AU6524794A (en) * 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
EP0777684B1 (de) * 1994-08-16 2004-04-28 Human Genome Sciences, Inc. Calcitoninrezeptor
WO1998003534A1 (en) * 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
CN1055640C (zh) * 1996-11-29 2000-08-23 沃维汉 人降钙素基因相关肽脂质体组合物及其制法
DE69943039D1 (de) * 1998-02-13 2011-01-27 Amylin Pharmaceuticals Inc Neue verbindungen mit gemischter amylin aktivität

Also Published As

Publication number Publication date
AU2002356469A2 (en) 2003-06-10
EP1461068A4 (de) 2006-03-29
EP1461068A1 (de) 2004-09-29
AU2009201147A1 (en) 2009-04-23
JP2005523418A (ja) 2005-08-04
CN1617737A (zh) 2005-05-18
WO2003045424A1 (en) 2003-06-05
CA2471833A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2009201147A1 (en) Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues
Mera et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise
US7803557B2 (en) Methods for identification of eicosapentaenoic acid analogs using anti-inflammatory receptors
Kuei et al. Study of GPR81, the lactate receptor, from distant species identifies residues and motifs critical for GPR81 functions
Canatan et al. Relationship among levels of leptin and zinc, copper, and zinc/copper ratio in plasma of patients with essential hypertension and healthy normotensive subjects
Nakahara et al. Comparison of feeding suppression by the anorexigenic hormones neuromedin U and neuromedin S in rats
McKie et al. Biochemical adaptations in white adipose tissue following aerobic exercise: from mitochondrial biogenesis to browning
EP1817583A2 (de) Gene in zusammenhang mit glukosetransport, polypeptide und verfahren zu ihrer verwendung
Tollet-Egnell et al. Growth hormone-mediated alteration of fuel metabolism in the aged rat as determined from transcript profiles
US20040038861A1 (en) Methods and compositions for normalizing lipid levels in mammalian tissues
Nellemann et al. Kinetics and utilization of lipid sources during acute exercise and acipimox
WO2004055201A2 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
AU2016361783A1 (en) Agonist of spexin-based galanin type 2 receptor and use thereof
Wasilewski et al. Role of G protein-coupled orphan receptors in intestinal inflammation: novel targets in inflammatory bowel diseases
Sochal et al. Diagnostic value of chemerin in lower gastrointestinal diseases—A review
NZ542281A (en) Methods and compositions for normalizing muscle lipid levels using CGRP-1
WO2009036768A2 (en) Diagnosing potential weight gain in a subject
Oana et al. DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a β3-adrenoceptor agonist, KTO-7924
CA2577176A1 (en) Method of screening for a carnitine transporter agonist or antagonist and its uses
US7947458B1 (en) Placental human neurokinin B precursor
Tvarijonaviciute et al. Serum adiponectin concentration in dogs—absence of diurnal variation and lack of effect of feeding and methylprednisolone administration
Vargas-Sánchez et al. PPARα and PPARβ/δ Expression is Associated with Proinflammatory Markers in an Obese Pediatric Population
EP1137949A1 (de) Tests für verbindungen zur erhöhung phospholipase-a2 aktivität
Harant et al. Atrial natriuretic peptide contribution to lipid
JP2006290885A (ja) インスリン抵抗性およびインスリン抵抗性を特徴とする疾病状態の治療方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2004

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS AND COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted